Referring Clinicians

Thank you for your interest to consider your patients for early phase clinical trial enrollment. Here at the Auckland Cancer Trials Centre, we welcome referrals from across the whole of New Zealand.

This page contains the following information:

  • An updated list of trials currently enrolling at our unit.
  • Links to patient information summaries and key inclusion/exclusion criteria for each individual trial (feature in development)
  • Instructions on how to refer your patients

Trials Recruiting at ACTC 

Tumour StreamTrial NameStudy DescriptionKey Investigational AgentKey Inclusion CriteriaRecruitment Status
Multiple tumour streamGILEAD (GS-US-494-5484)A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the
Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in
Subjects with Advanced Solid Tumors
GS-4224 (small molecule oral PDL1 Inhibitor)Advanced Solid Organ Malignancy with no further treatment options.

TPS/CPS >10% in participants of the Biopsy Substudy
Recruitment Open
- Phase 1b Dose Escalation Cohort and Biopsy Substudy

Expected to open in 2nd quarter 2020
-Phase 2 Basket Dose Expansion Cohort: CPI Naïve -Melanoma, Renal, Urothelial, Gastric/GOJ, HNSCC,MSI High Cancer, Merkel Cell Carcinoma
Head and Neck Squamous Cell CarcinomaBP40234-FAPPhase 2 study to evaluate the therapeutic activity of RO6874281 in combination with Atezolizumab in patients with advanced and/or metastatic solid tumorsAtezolizumab (Anti PDL1) + IL2variantHNSCC
-Checkpoint inhibitor exposed (≥ 2nd line)
Recruiting
Upper Gastrointestinal (Advance) , Colorectal (Advance)CITRONReducing Oxaliplatin Neurotoxicity: A Phase IB Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose-Finding and Proof-of-Concept Trial of Cimetidine in Gastrointestinal Cancer PatientsmFOLFOX OR CAPOX +/- cimetidineFirst 2 cycles mFOLFOX + cimetidine or placebo assessing for acute neuropathy.Recruiting
Colorectal (Metastatic)MedimmuneA phase 1/2 study of Durvalumab and Monalizumab in Adult Subjects with Select Advance Solid TumoursDurvalumab (antiPDL1) [D] +
Monalizumab (anti CD94/NKG2A) [M] +
Cetuximab (EGFR inhibitor) [C]
Cohort C2 : RAS, BRAF wildtype, microsatelite stable, must have been exposed to 5FU/Oxali/Irinotecan/Bevacizumab in 1 or 2 lines of therapy. Randomised to either (D+M+C) or (M+C)Recruiting
Merkel Cell MK-3475-913A phase 1 open label, multi-arm , multicenter study of MK-1308 in combination with pembrolizumab for subjects with advanced solid organ tumoursPembrolizumab(antiPD1)• Unresectable Stage III and Stage IV Merkel Cell Carcinoma
• 1st line
Recruiting
Prostate (mCRPC)MK-3475-365Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) Pembrolizumab +Olaparib or Pembrolizumab +AbirateroneCohort A: (Pembro + Olaparib)- Must have received docetaxel +/- second chemo agent, up to 2 generation hormonal manipulations allowed (e.g. abiraterone, enzalutamide)

Cohort D (Pembro + Abiraterone + Pred)- Chemo naïve for mCRPC (docetaxel allowed in mCNPC setting), no prior 2ng generation hormonal manipulation OR progressed on enzalutamide.
Recruiting
Melanoma (Fully resected stage III and IV)CA2098FCPhase 1, randomized, double-blinded study to compare the PK of Process D Nivolumab to Process C Nivolumab administered after complete resection of Stage IIIa/b/c/d or Stage IV Melanoma Nivolumab (Process D)Completely resected Stage III/ IV Melanoma
Randomization within 12 weeks of definitive surgery.
No adjuvant radiotherapy permitted
Recruitment open but all available slots have been allocated to already referred patients
Melanoma, NSCLC, SCLCNP40435Phase 1b study to evaluate safety, pharmacokinetic and preliminary anti-tumour activity of R07121661, PD-l/TIM3 Bispecific Antibody in patients with advanced and/or metastatic solid tumoursPD1/TIM3 bi-specific antibody-Melanoma: after PD1+/- CTLA4 inhibitor (includes uveal melanoma)
-NSCLC: CPI experienced, post platinum, must have received at least 4 months of CPI, PDL1>1%
-SCLC: CPI-naive
Recruitment to commence soon

How to Refer 

Please email all referrals to CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)

Email us for any other inquiries: infoACTC@adhb.govt.nz

 

Auckland Cancer Trials Centre

Auckland City Hospital,

2, Park Road, Grafton,

1023, Auckland, New Zealand

Patient Referrals 

Please email all referrals to: CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)

Email us for any other inquiries:

infoACTC@adhb.govt.nz